Our Primary Care unit offers solutions that help patients and health care providers manage chronic, costly conditions, and improve outcomes and overall health. Through leadership in areas such as the management of pain, heart disease and depression, Primary Care medicines treat conditions that account for a large and growing portion of the world's health care costs. Our pipeline includes molecules with potential in women's health, pain, cardiovascular and metabolic diseases, allergy and respiratory, and Alzheimer's disease and other dementias.
Eliquis (apixaban) approved in Europe for the prevention of venous thromboembolism (blood clots) in joint replacement patients; accepted for review in Europe and the U.S. for stroke prevention in patients with atrial fibrillation.
Oxecta (oxycodone HCL, USP), Tablets CII approved in the U.S. for management of acute and chronic pain and utilizing technologies designed to deter abuse and misuse.
Completed acquisition of King Pharmaceuticals, supplementing Pfizer's long-standing strength in pain management.
Completed acquisition of Icagen, Inc., an innovative leader in pain research, adding extensive research expertise and technology in the field of ion channels and enhancing Pfizer's ability to develop potential first-in-industry drugs for the treatment of pain and related conditions.